Cargando…

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment

Detalles Bibliográficos
Autores principales:	Shaughnessy, Ciaran A., Zeitlin, Pamela L., Bratcher, Preston E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546072/ https://www.ncbi.nlm.nih.gov/pubmed/34697341 http://dx.doi.org/10.1038/s41598-021-00539-5

Ejemplares similares

Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment
por: Shaughnessy, Ciaran A., et al.
Publicado: (2021)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings
por: Bratcher, Preston E., et al.
Publicado: (2020)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
por: Veit, Guido, et al.
Publicado: (2020)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
por: Lefferts, Juliet W., et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021)

Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis
por: Bacalhau, Mafalda, et al.
Publicado: (2023)

Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
por: Cavinato, Luca, et al.
Publicado: (2023)

Author Correction: CFTR function, pathology and pharmacology at single-molecule resolution
por: Levring, Jesper, et al.
Publicado: (2023)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022)

Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022)

Author Correction: New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation
por: Bitam, Sara, et al.
Publicado: (2021)

Author Correction: Spatial covariance analysis reveals the residue-by-residue thermodynamic contribution of variation to the CFTR fold
por: Anglès, Frédéric, et al.
Publicado: (2022)

Downregulation of epithelial sodium channel (ENaC) activity in human airway epithelia after low temperature incubation
por: Yadav, Sangya, et al.
Publicado: (2021)

Correction to: L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fbrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
por: Lo Cicero, Stefania, et al.
Publicado: (2023)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Optimism with Caution: Elexacaftor–Tezacaftor–Ivacaftor in Patients with Advanced Pulmonary Disease
por: Kuek, Stephanie L., et al.
Publicado: (2021)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis
por: Causer, Adam J., et al.
Publicado: (2022)

383: Cystic fibrosis macrophage function after elexacaftor/tezacaftor/ivacaftor initiation
por: Zhang, S., et al.
Publicado: (2021)

THE IMPACT OF TRIKAFTA (ELEXACAFTOR/IVACAFTOR/TEZACAFTOR) ON PATIENTS WITH CYSTIC FIBROSIS WITH COVID-19
por: MILES, B., et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor Accelerates Wound Repair in Cystic Fibrosis Airway Epithelium
por: Laselva, Onofrio, et al.
Publicado: (2022)

Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
por: Pallenberg, Sophia T., et al.
Publicado: (2022)

The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis
por: Allgood, Sarah, et al.
Publicado: (2023)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
por: Tsai, Alice, et al.
Publicado: (2020)

Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure
por: Nick, Heidi J., et al.
Publicado: (2021)

Author Correction: Multivariate information theory uncovers synergistic subsystems of the human cerebral cortex
por: Varley, Thomas F., et al.
Publicado: (2023)

Author Correction: Improving the accuracy of medical diagnosis with causal machine learning
por: Richens, Jonathan G., et al.
Publicado: (2021)

Author Correction: Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia
por: Huang, Zhu, et al.
Publicado: (2023)

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial
por: Nichols, David P., et al.
Publicado: (2021)

Change in Lung Function after Initiation of Elexacaftor–Tezacaftor–Ivacaftor: Do Not Forget Anatomy!
por: Martin, Clémence, et al.
Publicado: (2022)

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)

Immunoreactive Trypsinogen in Infants Born to Women with Cystic Fibrosis Taking Elexacaftor–Tezacaftor–Ivacaftor
por: Patel, Payal, et al.
Publicado: (2023)

Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
por: Gramegna, Andrea, et al.
Publicado: (2023)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
por: Kapouni, Nikoletta, et al.
Publicado: (2023)

Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash
por: Santos, Ana Isabel, et al.
Publicado: (2023)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Author Correction: Chronic kidney disease and pregnancy outcomes
por: Dvořák, Jan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bhkktb0mvq5h6oaab0lrcbch3o